Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Niagen BioscienceFRA:OCD1 67 Quick Ratio is 3.55 as of Mar. 2026, which is 79% above its 10-year median of 1.98. GuruFocus rates FRA:OCD1 with a GF Score™ of 67/100 and a GF Value™ of €3.98 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,409 Biotechnology companies, Niagen Bioscience ranks worse than 50.46% on this metric.
Niagen Bioscience has a quick ratio of 3.55. It generally indicates good short-term financial strength.
The historical rank and industry rank for Niagen Bioscience's Quick Ratio or its related term are showing as below:
FRA:OCD1'
s Quick Ratio Range Over the Past 10 Years
Min: 0.62 Med: 1.98 Max: 6.35
Current: 3.55
During the past 13 years, Niagen Bioscience's highest Quick Ratio was 6.35. The lowest was 0.62. And the median was 1.98.
FRA:OCD1's Quick Ratio is ranked worse than 50.46% of 1409
companies
in the Biotechnology industry
Industry Median: 3.59
vs FRA:OCD1: 3.55
Niagen Bioscience (FRA:OCD1) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Niagen Bioscience Quick Ratio Related Terms
Niagen Bioscience Quick Ratio Historical Data
* Premium members only.
The historical data trend for Niagen Bioscience's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:OCD1 vs LCTX, IFRX, VRXA: Quick Ratio Comparison
For the Biotechnology subindustry, Niagen Bioscience's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Niagen Bioscience Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Niagen Bioscience's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Niagen Bioscience's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Niagen Bioscience's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Niagen Bioscience (FRA:OCD1) has a Quick Ratio of 3.55 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Niagen Bioscience and its competitors. This is 79% above median its historical median of 1.98. Over the past decade, Niagen Bioscience's Quick Ratio has ranged from 0.62 to 6.35. According to the industry distribution chart, Niagen Bioscience ranks #711 out of 1409 companies in the Biotechnology industry, placing it in the top 50.5%.
Is Niagen Bioscience's Quick Ratio too high?
Niagen Bioscience's current Quick Ratio of 3.55 is 79% above median its 10-year median of 1.98. Over the past 10 years, this metric has ranged from a low of 0.62 to a high of 6.35. The Biotechnology industry median Quick Ratio is 3.59. Niagen Bioscience's value of 3.55 is 1.1% below this industry median. Based on the distribution chart, Niagen Bioscience ranks #711 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Niagen Bioscience has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Niagen Bioscience's Quick Ratio compare to LCTX and IFRX?
According to the Biotechnology industry distribution chart, Niagen Bioscience ranks #711 out of 1409 companies for Quick Ratio. This places Niagen Bioscience in the lower half of its industry. The industry median Quick Ratio is 3.59. Niagen Bioscience's value of 3.55 is 1.1% below this benchmark. Historically, Niagen Bioscience's own Quick Ratio has ranged from 0.62 to 6.35 over the past decade. While the company's 10-year median is 1.98 vs. the industry median of 3.59, Niagen Bioscience has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.59, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Niagen Bioscience's current Quick Ratio of 3.55 is 1.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Niagen Bioscience and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Niagen Bioscience's current Quick Ratio is 3.55, which is 79% above median its own 10-year median of 1.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Niagen Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Niagen Bioscience (FRA:OCD1) is currently considered Possible Value Trap. The stock's GF Value™ is €3.98, compared to a current price of €2.58 — trading 35.2% below its estimated fair value. The current Quick Ratio is 3.55, which is 79% above median its 10-year median of 1.98 and 1.1% below the Biotechnology industry median of 3.59. Niagen Bioscience's overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Niagen Bioscience (FRA:OCD1), the current Quick Ratio is 3.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Niagen Bioscience (FRA:OCD1) Overvalued in 2026?
Based on GuruFocus' analysis, Niagen Bioscience stock appears to be undervalued.
The current stock price of €2.58 is trading 35.2% below its estimated GF Value™ of €3.98.
GuruFocus considers Niagen Bioscience to be Possible Value Trap.
Key valuation signals for FRA:OCD1:
Quick Ratio: 3.55 (79% above median its 10-year median of 1.98)
GF Value™: €3.98 vs. price of €2.58 (35.2% below fair value)
Industry Position: 1.1% below the Biotechnology median (#711 of 1409)
No single metric tells the full story. See the FRA:OCD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
67GF Score
Get the complete analysis for FRA:OCD1
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OCD1 has been successfully added to your 
